News Related to Primary Progressive MS

Related coverage linked through entity extraction aliases.

CAR T-cell therapy trial for progressive MS now recruiting; stem cell transplant trials advance

Mar 06, 2026

A Phase 1 trial of azer-cel, a CAR T-cell therapy using donor T-cells to target B-cells, is recruiting patients with progressive multiple sclerosis at eight U.S. sites. Separately, multiple randomized trials are comparing hematopoietic stem cell transplantation against high-efficacy disease-modifying therapies.

Fenebrutinib Shows 12% Reduction in Disability Progression vs Ocrelizumab in PPMS Trial

Feb 25, 2026

Phase III FENtrepid trial results show investigational BTK inhibitor fenebrutinib met its primary endpoint of non-inferiority to ocrelizumab in primary progressive MS, with a 12% reduction in disability progression risk and strongest effect on upper limb function.